Sanofi Pumps $625M Into Venture Arm to Back Breakthroughs in Early-Stage Startups

With the new capital infusion, Sanofi Ventures’ total assets under management now tops $1.4 billion. Our recap of other financings includes startups raising money for novel therapies in development for autoimmune disease, neurological disorders, cancer, and more. The post Sanofi Pumps $625M Into Venture Arm to Back Breakthroughs in Early-Stage Startups appeared first on MedCity…

Read More

Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis, a relatively rare name a few years back, has seen a significant jump in cases in the past few years, mainly the ones following COVID-19. Recently, this illness has found its way into the news following being the cause that claimed the life of Zakir Hussain, an eminent musical maestro who redefined…

Read More

CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies

Caribou Biosciences’ restructuring narrows the biotech’s focus to two off-the-shelf cell therapies for blood cancers, whose key data readouts have been pushed out to the second half of 2025. It’s the CRISPR-editing company’s second cash-saving restructuring in the past year. The post CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on…

Read More

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

That is the title of a new paper out last week in Future Oncology with co-authors Kejal Jadhav, Cheryl Warren, Sabiha Quddus, Nadine Zawadzki, Daisy Yang, Andrea Damon, Kathryn Spurrier, Katharine Batt and David Wei. The abstract is below. ObjectiveTyrosine kinase inhibitors (TKIs) have transformed the prognosis of chronic myeloid leukemia (CML) into a manageable…

Read More